Esperion(ESPR) - 2024 Q1 - Quarterly Results
Esperion(ESPR)2024-05-07 11:29– Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non- Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Primary and Secondary Prevention Patients – ® ® Exhibit 99.1 Esperion Reports First Quarter 2024 Financial Results – Q1 Total Re ...